Taysha Gene Therapies (TSHA) EPS (Basic) (2020 - 2026)
Taysha Gene Therapies (TSHA) posted EPS (Basic) of -$0.12 for Q1 2026, down 32.79% sequentially from -$0.09 in Q4 2025, and down 44.7% YoY from -$0.21 in Q1 2025.
Powered by 
Analysis
Taysha Gene Therapies (TSHA) EPS (Basic) (2020 - 2026) Analysis & Trends
Taysha Gene Therapies has reported EPS (Basic) for 7 years, with the latest figure at -$0.12 in Q1 2026.
- Quarterly EPS (Basic) fell 44.7% year-over-year to -$0.12 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$0.35 (down 9.95% YoY) and the FY2025 annual result came in at -$0.34, up 4.51% from the prior year.
- EPS (Basic) slipped to -$0.12 in Q1 2026 per TSHA's latest filing, from -$0.09 in the prior quarter.
- Over five years, EPS (Basic) peaked at $0.41 in Q4 2023 and troughed at -$1.32 in Q1 2022.
- A 5-year average of -$0.36 and a median of -$0.1 in 2024 frame the typical range for EPS (Basic).
- The sharpest annual moves came in 2023 and 2024: EPS (Basic) surged 132.81% in 2023, then tumbled 118.27% in 2024.
- Over 5 years, EPS (Basic) stood at -$1.25 in 2022, then surged by 132.81% to $0.41 in 2023, then tumbled by 118.27% to -$0.08 in 2024, then declined by 16.0% to -$0.09 in 2025, then slumped by 32.79% to -$0.12 in 2026.
- According to Business Quant data, EPS (Basic) over the past three periods registered -$0.12, -$0.09, and -$0.09 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 4.34 |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 12.62 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 7.70 |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -1.96 |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -3.06 |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 2.12 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 1.23 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 0.18 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.06 |
| 10 | Taysha Gene Therapies | 2.06 Bn | 2.06 Bn | - | -0.13 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -0.13 |
| Mar 31, 2026 | -0.12 |
| Dec 31, 2025 | -0.09 |
| Sep 30, 2025 | -0.09 |
| Jun 30, 2025 | -0.09 |
| Mar 31, 2025 | -0.08 |
| Dec 31, 2024 | -0.08 |
| Sep 30, 2024 | -0.10 |
| Jun 30, 2024 | -0.09 |
| Mar 31, 2024 | -0.10 |
| Dec 31, 2023 | 0.41 |
| Sep 30, 2023 | -0.93 |
| Jun 30, 2023 | -0.38 |
| Mar 31, 2023 | -0.28 |
| Dec 31, 2022 | -1.25 |
| Sep 30, 2022 | -0.65 |
| Jun 30, 2022 | -0.85 |
| Mar 31, 2022 | -1.32 |
| Dec 31, 2021 | -1.34 |
| Sep 30, 2021 | -1.35 |